ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs

January 31, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 31, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mimi Huizinga, MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs.

“As evidence generation and stakeholder engagement play increasingly important roles in delivering innovative therapies to patients, Medical Affairs has evolved to a third strategic pillar of our business, alongside R&D and Commercial,” said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. “With her clinical experience, medical and data analytics expertise, and strong relationships with key stakeholders in the field of oncology, I am pleased to welcome Mimi to ImmunoGen’s executive team to lead our growing Medical Affairs organization. In this newly-created position, she will play a critical role as we work to bring our lead candidate, mirvetuximab soravtansine, to women living with ovarian cancer in the second half of this year and advance the rest of our portfolio of novel ADCs.”

Dr. Huizinga joins ImmunoGen from Rafael Holdings where she served as Chief Medical Officer and Head of Research and Development and was responsible for leading the Company’s discovery and development programs. Prior to joining Rafael, she served as SVP, Head of US Oncology Medical for Novartis, overseeing the clinical development and medical affairs activities of the Novartis oncology portfolio in the US. Before leading the medical function, Dr. Huizinga built and led the strategic data and digital function for the US Oncology business unit at Novartis. During her time at Novartis, she participated in more than a dozen product and indication launches. Prior to Novartis, Dr. Huizinga was the Chief Health Information Officer at Premier, Inc., where she led quality and population health strategies and the Applied Sciences division that formed partnerships with a number of pharmaceutical companies around evidence generation needs. Earlier in her career, Dr. Huizinga served as the VP of Quality at Lifepoint Health, was an associate at McKinsey & Company, and an Assistant Professor at Johns Hopkins University School of Medicine. She serves as an independent director at HealthMyne, a radiomics company. Dr. Huizinga holds an MD and MPH from Vanderbilt University and is a fellow of the American College of Physicians.

“I am excited to join ImmunoGen at such an important time, and to lead a growing global Medical Affairs function that supports the launch of our pivotal programs and the development of our earlier stage assets,” said Dr. Huizinga. “Healthcare innovation is my passion and I look forward to building a team focused on delivering high-quality data, education, and outcomes for patients, caregivers, healthcare professionals, and payors.”

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the occurrence, timing, and outcome of regulatory events related to the Company's product candidates, in particular with respect to mirvetuximab soravtansine, and the launch of mirvetuximab soravtansine in the second half of 2022; and the Company's business and product development of novel ADCs. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company's preclinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes, including approval of the Company's biologics license application for mirvetuximab soravtansine; the Company's ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen's industry and business; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, and other reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005121/en/

INVESTOR RELATIONS AND MEDIA CONTACTS
ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.